Sign in with your email address username.


[Correspondence] The promise of personalised medicine

I read with great interest the Viewpoint by Victor Dzau and colleagues (May 23, p 2118)1 who suggested that personalised and precision medicine would result in identification of patients at highest risk of six high-prevalence diseases (cancer, diabetes, heart disease, hypertension, lung disease, and stroke) and lead to subsequent early prophylactic intervention. The authors also suggested that personalised medicine could lead to substantial cumulative gains (expressed using US$100 000 per quality-adjusted life-year, with a $33 billion gain at a reduced disease incidence of 10% and up to a $607 billion gain at a 50% incidence reduction) in life expectancy and quality-adjusted life expectancy during the subsequent 50 years.